Other examples include the use of the EV-associated lactadherin (C1C2 domain), which has been fused to anti-Her2 single-chain variable fragments to target HER2-positive breast cancer[192], glycosylphosphatidylinositol (GPI) fused to anti-EGFR nanobodies for cancer targeting[193], and platelet-derived growth factor receptors (PDGFRs) fused to the EGFR binding peptide GE11[194]. Here, ERBB2 is linked to breast carcinoma.